CAGE Bio Launches Phase 2b Trial for Atopic Dermatitis Treatment CGB-500

CAGE Bio Inc., located in San Carlos and Fort Worth, has initiated a Phase 2b trial for its topical JAK inhibitor, CGB-500. This trial aims to optimize dosing and further evaluate the treatment's safety and efficacy for moderate to severe atopic dermatitis (AD). The ointment, developed using the company's proprietary ionic liquid technology, targets low body surface area conditions.

The 2024 Phase 2a trial displayed remarkable results, with an 8-week success rate of 95%, comparable to biologics and superior to existing topical treatments. The ongoing Phase 2b trial involves 180 participants and emphasizes balancing efficacy and side effects.

CGB-500 delivers medication directly through the skin with minimal systemic exposure, offering a potential solution for patients seeking localized relief. The trial reflects CAGE Bio's dedication to addressing unmet needs in AD treatment.